GE Healthcare sales and profit rise in Q2
In one of the last financial quarters before being spun out as an independent...Read more on AuntMinnie.comRelated Reading: GE to spin off GE Healthcare into standalone company GE releases new systems, software at SNMMI 2018 GE to be booted from Dow Jones Industrial Average GE taps McGuinness to lead Imaging division GE inks analytics deal with Florida Hospital (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 20, 2018 Category: Radiology Source Type: news

GE Healthcare ’ s Q2 profits jump 12%
Second-quarter profits for the healthcare business at General Electric (NYSE:GE) rose more than 12% as its parent corporation eked out earnings and sales beats for the three months ended June 30. GE Healthcare’s profits rose 12.1% to $926 million on sales growth of 6.2% to $4.98 billion compared with Q2 2017 as it prepares to be spun out as a standalone company. Overall profits for GE were off -29.7% to $615 million, or 7¢ per share, on sales growth of 3.5% to $30.10 billion. Adjusted to exclude one-time items, earnings per share were 19¢, a penny ahead of the consensus on Wall Street, where analy...
Source: Mass Device - July 20, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat GE Healthcare Source Type: news

Intuitive Surgical posts Street-beating Q2
Shares in Intuitive Surgical (NSDQ:ISRG) have risen in after-hours trading after the robotic surgical platform maker beat expectations on Wall Street with its second quarter results. The Sunnyvale, Calif.-based company posted profits of $254.6 million, or $2.15 per share, on sales of $909.3 million for the three months ended June 30, for bottom-line growth of 14.2% on sales growth of 19.7% compared with the same period during the previous year. Adjusted to exclude one-time items, earnings per share were $2.76, well ahead of the $2.50 consensus on Wall Street, where analysts expected to see sales of $877.6 million, whi...
Source: Mass Device - July 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Intuitive Surgical Source Type: news

As Q2 revenue takes expected dip, NeuroMetrix looks to recoup with updated product launch, GSK partnership
Earnings reports shared by neurostimulation and digital medicine company NeuroMetrix during a Q2 investors ’ call showed a slight drop in total revenue as the company is preparing to place its marketing weight behind the launch of its updated wearable pain relief product, Quell. However, the company remained profitable during the quarter thanks to sales of its other product, DPNCheck. (Source: mobihealthnews)
Source: mobihealthnews - July 19, 2018 Category: Information Technology Source Type: news

Establishment Labs prices $67m IPO
Breast implant maker Establishment Labs yesterday priced its initial public offering at $18 per share, saying it expects to gross nearly $67 million not including a possible underwriters option. Alajuela, Costa Rica-based Establishment Labs originally registered the offering at $58 million, saying it plans to use the proceeds to fund a pre-market approval study of its Motiva implants. The FDA granted an investigational device exemption in March for the PMA study and enrolled the first patient the next month, the company said. Yesterday the company said it’s offering some 3.7 million shares at...
Source: Mass Device - July 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cosmetic/Aesthetic Funding Roundup Initial Public Offering (IPO) Wall Street Beat Women's Health Establishment Labs Source Type: news

Abbott Labs raises 2018 earnings forecast, shares hit record high
Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions. (Source: Reuters: Health)
Source: Reuters: Health - July 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis posts Q2 beat, promises to hold off on drug price hikes
Shares in Novartis (NYSE:NVS) were up today after the company beat expectations on Wall Street with its second-quarter financial results. The Switzerland-based company posted profits of $7.77 billion, or $3.34 per share, on sales of $13.16 billion for the three months ended June 30. Novartis saw its quarterly sales climb 7% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Novartis posts Q2 beat, promises to hold off on drug price hikes appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 18, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Novartis Source Type: news

Sales for Abbott ’s diabetes business jump 40% in Q2
Abbott (NYSE:ABT) shares were up today after the healthcare company posted second-quarter financial results that topped estimates on Wall Street. For the three months ended June 30, Abbott posted profits of $733 million, or 41¢ per share, on sales of $7.77 billion. The company saw its quarterly profits grow 159% on sales growth of 17% compared with Q2 2017. Get the full story at our sister site, Drug Delivery Business News. The post Sales for Abbott’s diabetes business jump 40% in Q2 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 18, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Vascular Wall Street Beat Abbott Source Type: news

Abbott Labs tops profit estimates, raises full-year earnings forecast
Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit. (Source: Reuters: Health)
Source: Reuters: Health - July 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Abbott ’ s Q2 results top estimates, medical device sales up 11%
Abbott (NYSE:ABT) today reported second-quarter results that came in ahead of the consensus expectation, with its medical device division posting sales growth of more than 11%, and raised its earnings outlook for the rest of the year. The Chicago-area healthcare giant posted profits of $733 million, or 41¢ per share, on sales of $7.77 billion for the three months ended June 30, for profit growth of 159.0% on sales growth of 17.0% compared with Q2 2017. Adjusted to exclude one-time items, earnings per share were 73¢, two pennies ahead of Wall Street, where analysts were looking for sales of $7.71 billion. Abbott&r...
Source: Mass Device - July 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Abbott Source Type: news

J & J beats quarterly expectations on drug sales surge, shares jump
Johnson& Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade, and its shares rose more than 4 percent. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beat fueled by strength in pharma business
Johnson& Johnson topped analysts' estimates for quarterly profit and revenue on Tuesday, as strong demand for cancer drugs Zytiga and Darzalex more than made up for declining sales of blockbuster treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Anchored By Optum's Reach, UnitedHealth's Profits Jump
UnitedHealth Group's profits jumped 28% in the second quarter on increased sales of both health plans and a menu of Optum health services including pharmacy benefit management, surgical and outpatient care. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 17, 2018 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Tags: NYSE:UNH NYSE:CVS NYSE:HUM NYSE:ANTM NYSE:AET Source Type: news

Johnson & Johnson tightens outlook as Q2 results top forecast
Second-quarter sales and earnings topped the consensus forecast today for Johnson & Johnson (NYSE:JNJ), prompting the healthcare giant to tighten its outlook on the rest of the year. New Brunswick, N.J.-based J&J posted overall profit growth of 3.1% to $3.95 billion, or $1.45 per share, on sales growth of 10.6% to $20.83 billion for the three months ended June 30, compared with Q2 2017. Johnson & Johnson’s largest division, pharmaceuticals, drove the lion’s share, growing revenues 19.9% to $10.35 billion. Adjusted to exclude one-time items, earnings per share were $2.10, 3¢ ahead of the co...
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat johnsonandjohnson Source Type: news

AngioDynamics CEO Clemmer is on the M & A trail
AngioDynamics (NSDQ:ANGO) CEO Jim Clemmer said the company is actively walking the M&A trail as it looks at markets with unmet needs and high margins. Latham, N.Y.-based AngioDynamics posted fiscal fourth-quarter results July 11 that missed Wall Street’s expectations, sending share prices down some -9% this week despite a swing to black ink. During a conference call discussing the results, Clemmer said one aspect of the turnaround he was hired to engineer involves acquisition and, perhaps, even selling off some assets. Citing “portfolio optimization” as the goal, the Covidien veteran said the ext...
Source: Mass Device - July 13, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Wall Street Beat AngioDynamics Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight The MAReport: Check out the Spring 2018 issue of the MAReport newsletter! This quarter, Executive Director Kate Flewelling talked about attending the All of Us launch event at the historic Abyssinian Baptist Church in Harlem, New York City. Call for Applicants for the Sewell Stipend to Attend the 2018 APHA Annual Meeting – Is your position related to public health? Would you like an opportunity to immerse yourself in the public health field for a few days? Apply for the Sewell Travel Award for Public Health and attend...
Source: NN/LM Middle Atlantic Region Blog - July 13, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

A time to celebrate
This year, our union celebrates an important milestone: our 25th anniversary. Formed by the merger of three great unions – NALGO, NUPE and COHSE – we were told that our efforts were doomed to failure. We were told that UNISON would not work. In the years since, UNISON’s downfall has been predicted on countless occasions by opponents who constantly underestimated our union and our members. Of course, we all know how wrong the doom-mongers were. As the people who heal us, educate us, keep us safe and ensure that we receive care, support and vital services every single day, UNISON people are special people, ...
Source: UNISON meat hygiene - July 12, 2018 Category: Food Science Authors: Dave Prentis Tags: Article Magazine Source Type: news

About Half of Americans Say They ’re Trying to Lose Weight
If you’re trying to lose weight, new data says that you’re far from alone. 49% of American adults surveyed between 2013 and 2016 reported trying to lose weight at some point during the prior 12 months, according to a report from the Centers for Disease Control and Prevention’s National Center for Health Statistics (NCHS). Women were more likely than men to report trying to lose weight, finds the data, which is based on responses to the National Health and Nutrition Examination Survey. That finding held true overall — 56.4% of women said they had tried to slim down, versus 41.7% of men — and in...
Source: TIME: Health - July 12, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Diet/Nutrition healthytime onetime Source Type: news

AngioDynamics takes a hit after missing Q4 numbers
AngioDynamics (NSDQ:ANGO) failed to meet expectations for its fiscal fourth quarter, sending share prices sharply down today despite a swing to black ink. Latham, N.Y.-based AngioDynamics posted profits of $2.1 million, or 6¢ per share, on sales of $88.3 million for the three months ended May 31. That compares with losses of -$12.9 million during fiscal Q4 2017 and amounts to top-line growth of 1.6%. Adjusted to exclude one-time items, earnings per share were 20¢, a penny below the consensus forecast on Wall Street, where analysts were looking for sales of $89.3 million. Full-year profits surged 226.2% to $1...
Source: Mass Device - July 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat AngioDynamics Source Type: news

Bovie Medical to deal core electro-cautery biz to Symmetry Surgical for $97m
Bovie Medical (NYSE:BVX) shares rode a roller coaster today on the news that it’s dealing its core electro-cautery business to Symmetry Surgical for $97 million and is on track to beat estimates with its second-quarter sales. Clearwater, Fla.-based Bovie, which is making a pivot toward the cosmetic surgery market, said the all-cash deal for the electrosurgical and cauteries business includes its namesake brand. It also involves transition services, patent licensing, disposables supply and generator manufacturing agreements; Bovie said the latter term sets it up as an OEM supplier to Symmetry “at least...
Source: Mass Device - July 9, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Surgical Wall Street Beat Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight The MAReport: Check out the Spring 2018 issue of the MAReport newsletter! This quarter, our Spring intern Sheryl R. Simon, MD, wrote about the importance of precision medicine in cancer research and treatment. Call for Applicants for the Sewell Stipend to Attend the 2018 APHA Annual Meeting – Is your position related to public health? Would you like an opportunity to immerse yourself in the public health field for a few days? Apply for the Sewell Travel Award for Public Health and attend the 2018 American Public ...
Source: NN/LM Middle Atlantic Region Blog - July 6, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

New & Resurgent Infectious Diseases Can Have Far-reaching Economic Repercussions
DAVID E. BLOOM is the Clarence James Gamble Professor of Economics and Demography, DANIEL CADARETTE is a research assistant, and JP SEVILLA is a research associate, all at Harvard University’s T.H. Chan School of Public Health.By David E. Bloom, Daniel Cadarette and JP SevillaWASHINGTON DC, Jul 3 2018 (IPS)Infectious diseases and associated mortality have abated, but they remain a significant threat throughout the world.We continue to fight both old pathogens, such as the plague, that have troubled humanity for millennia and new pathogens, such as human immunodeficiency virus (HIV), that have mutated or spilled over ...
Source: IPS Inter Press Service - Health - July 3, 2018 Category: International Medicine & Public Health Authors: David E. Bloom and JP Sevilla Tags: Active Citizens Development & Aid Economy & Trade Global Headlines Health TerraViva United Nations Source Type: news

Neuronetics prices $94m offering
Neuronetics today priced its upcoming initial public offering, expecting to raise approximately $93.5 million to support its NeuroStar transcranial magnetic stimulation system designed to treat patients with major depressive disorder who aren’t responding to medication. The Malvern, Penn.-based company said it is looking to float 5.5 million shares of its common stock at $17 per share in its IPO. The offering also includes a 30-day underwriter’s option to purchase an additional 825,000 shares, which could net an additional $14.5 million for the company. Shares are expected to begin trading today under the ...
Source: Mass Device - June 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Initial Public Offering (IPO) Neurological Neuronetics Source Type: news

Neuronetics prices $94m IPO
Neuronetics today priced its upcoming initial public offering, expecting to raise approximately $93.5 million to support its NeuroStar transcranial magnetic stimulation system designed to treat patients with major depressive disorder who aren’t responding to medication. The Malvern, Penn.-based company said it is looking to float 5.5 million shares of its common stock at $17 per share in its IPO. The offering also includes a 30-day underwriter’s option to purchase an additional 825,000 shares, which could net an additional $14.5 million for the company. Shares are expected to begin trading today under the ...
Source: Mass Device - June 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Initial Public Offering (IPO) Neurological Neuronetics Source Type: news

General Electric to spin out GE Healthcare
General Electric (NYSE:GE) said today that it plans to spin out its GE Healthcare subsidiary as a stand-alone, publicly traded entity to focus on its aviation, power and renewable energy businesses. The Boston-based industrial conglomerate also said it’s planning an “orderly separation” from its 62.5% stake in BHGE oil and gas servicing and equipment unit over the next two to three years. Little Chalfont, U.K.-based GE Healthcare has long been a bright spot for its parent, consistently posting sales and profit gains despite overall declines at GE. In April division agreed to sell&...
Source: Mass Device - June 26, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Hospital Care Imaging Wall Street Beat GE Healthcare General Electric Source Type: news

Glaukos wins FDA PMA for iStent inject glaucoma device
Glaukos (NYSE:GKOS) said today it won FDA premarket approval for its iStent inject trabecular micro-bypass system. With the clearance, the iStent inject is now indicated for use in the reduction of intraocular pressure in adults with mild to moderate primary open-angle glaucoma who are undergoing concomitant cataract surgery. San Clemente, Calif.-based Glaukos said the iStent inject is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It uses a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecu...
Source: Mass Device - June 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Pre-Market Approval (PMA) Regulatory/Compliance Glaukos Source Type: news

Argus downgrades Zimmer Biomet
Declining sales and the supply & manufacturing issues that have bedeviled Zimmer Biomet (NYSE:ZBH) recently prompted an Argus analyst to downgrade the orthopedic giant’s stock today. Argus analyst David Toung moved ZBH shares from a “buy” to a “hold” rating based on the company’s estimate that it would be the second quarter before it returned to full inventory levels. But the FDA in February released a Form 483 sent to Zimmer Biomet that flagged issues found during an inspection of a former Biomet plant in Warsaw, Ind., last year, laying out eight observations it determined...
Source: Mass Device - June 22, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Orthopedics Wall Street Beat zimmerbiomet Source Type: news

Breast implant maker Establishment Labs registers for $58m IPO
Breast implant maker Establishment Labs yesterday registered for an initial public offering worth nearly $58 million, saying it plans to use the proceeds to fund a pre-market approval study of its Motiva implants. The FDA granted an investigational device exemption in March for the PMA study and enrolled the first patient the next month, the company said. Alajuela, Costa Rica-based Establishment Labs said the $57.5 million flotation will also be used to pay off $5 million worth of promissory notes due to former Class Z preferred shareholders and for general corporate purposes. The company plans to trade shares on the ...
Source: Mass Device - June 22, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cosmetic/Aesthetic Funding Roundup Wall Street Beat Establishment Labs Source Type: news

Portland-area hospitals score well on quality and profitablity in new analysis
Even as margins have edged down in recent quarters, area medical centers are mostly striking a balance between making money and maintaining quality, according to FT Ratings. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 21, 2018 Category: Health Management Authors: Elizabeth Hayes Source Type: news

Portland-area hospitals score well on quality and profitablity in new analysis
Even as margins have edged down in recent quarters, area medical centers are mostly striking a balance between making money and maintaining quality, according to FT Ratings. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 21, 2018 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

Dr. Gawande tapped to lead Amazon-JPM-Berkshire health play | Personnel Moves – June 21, 2018
The joint healthcare venture between Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan Chase said this week it named Brigham and Women’s Hospital surgeon, New Yorker magazine staff writer and bestselling author Dr. Atul Gawande as its CEO, effective July 9. The joint venture said that the newly formed company will be headquartered in Boston, and will operate as an independent entity free from profit-making incentives and constraints. Dr. Gawande also serves as a professor of Harvard Medical School and the Harvard T.H. Chan School of Public Health, and is the founding executive director of health system...
Source: Mass Device - June 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News AirXpanders Amazon Avantis Medical Systems Inc. Berkshire Hathaway Boston Scientific CHF Solutions Inc. Corindus Vascular Robotics Haemonetics Intuitive Surgical IsoRay JP Morgan Chase medicen Medtronic Source Type: news

Temple looking at possible sale of Fox Chase Cancer Center, Jeanes Hospital
Temple University Board of Trustees, looking to ensure the "financial stability and long-term viability" of its health system, is hiring a financial advisor to pursue strategic options that could include the potential sale of Fox Chase Cancer Center and/or Jeanes Hospital. No final decision has been made regarding these two facilities, according to Temple officials. For the first three quarters of fiscal 2016, which ended March 31, the health system recorded losses of more than $31 million. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 20, 2018 Category: Pharmaceuticals Authors: John George Source Type: news

Temple looking at possible sale of Fox Chase Cancer Center, Jeanes Hospital
Temple University Board of Trustees, looking to ensure the "financial stability and long-term viability" of its health system, is hiring a financial advisor to pursue strategic options that could include the potential sale of Fox Chase Cancer Center and/or Jeanes Hospital. No final decision has been made regarding these two facilities, according to Temple officials. For the first three quarters of fiscal 2016, which ended March 31, the health system recorded losses of more than $31 million. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 20, 2018 Category: Biotechnology Authors: John George Source Type: news

Haemonetics closes $700m debt refi
Haemonetics (NYSE:HAE) said today that it closed the refinancing of some $700 million in debt as part of its restructuring plan. Last November the Braintree, Mass.-based blood management company unveiled plans to cut roughly 11% of its global workforce as it looked to pare $80 million from its annual cash burn by the end of fiscal 2020. Today the company said it took out a new, $700 million credit line and used it to pay of $254 million in senior unsecured term loans due next June. The credit line includes a $350 million senior unsecured term loan and a $350 million senior unsecured revolving credit lin...
Source: Mass Device - June 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Blood Management Funding Roundup Wall Street Beat Haemonetics Source Type: news

Neuronetics adds up-to $12m over-allotment option to pending IPO
Neuronetics this week added an underwriter’s option to its initial public offering, which could bring in between $10.5 million and $12 million if fully exercised, and gave a rough price range for the offering. The Malvern, Penn.-based company said it is filing for the public offering to expand its commercialization efforts for the NeuroStar transcranial magnetic stimulation device for treating depression. Neuronetics now plans to offer a total of 5 million shares up front, expecting them to be priced between $14 and $16 per share, which would bring the total for the IPO to between $70 million and $80 million. Th...
Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Initial Public Offering (IPO) Neurological Wall Street Beat Neuronetics Source Type: news

Becoming the #1 Partner to Patient Groups
“We don’t partner with patient groups to have a good reputation,” says Amy Nicole Nayar, Head of Global Patient Relations at Abbvie. “If you want to partner with patient groups to improve your reputation, you will miss the mark.” An authentic intention to improve patient outcomes is the key factor to success.  We all want to be patient-centric, says Nayar. “There’s a reason why we all come to this industry,” she says.For her, it ’s personal – she grew up with a brother who had epilepsy and received an innovative treatment. Although it didn’t change...
Source: EyeForPharma - June 15, 2018 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Antarctica ’s Ice Is Melting Even Faster, and Scientists Are Deeply Worried
WASHINGTON — The melting of Antarctica is accelerating at an alarming rate, with about 3 trillion tons of ice disappearing since 1992, an international team of ice experts said in a new study. In the last quarter century, the southern-most continent’s ice sheet — a key indicator of climate change — melted into enough water to cover Texas to a depth of nearly 13 feet (4 meters), scientists calculated. All that water made global oceans rise about three-tenths of an inch (7.6 millimeters). From 1992 to 2011, Antarctica lost nearly 84 billion tons of ice a year (76 billion metric tons). From 2012 to 201...
Source: TIME: Science - June 13, 2018 Category: Science Authors: Associated Press Tags: Uncategorized climate change onetime Source Type: news

NuVasive launches AttraX scaffold bone graft biologic
NuVasive (NSDQ:NUVA) said today it launched its AttraX scaffold ceramic-collagen bone graft in the US, touting that the scaffold’s surface has been shown to increase bone formation for faster fusion than standard ceramic bone grafts. The San Diego-based company claims that the Attrax scaffold features a unique microstructure and microporosity that are optimized for bone formation, and that its AttraX surface technology drives the differentiation of mesenchymal stem cells into bone-forming osteoblasts without the need for added growth factors. “AttraX scaffold was easy to use and maintained excellent handli...
Source: Mass Device - June 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Spinal Nuvasive Source Type: news

Cook Medical to convert N.C.-based cigarette facility to med device factory
Cook Medical today announced plans to acquire a Winston-Salem, N.C.-based former cigarette facility, with plans to convert it into a medical device manufacturing facility. The 850,000 square-foot building, which was built in 1961 and ceased production in 2012, will house more than 650 local Cook Medical workers, the Bloomington, Ind.-based company said. The acquisition of the property is subject to conditions including inspections and finalizations with the city of Winston Salem, Forsyth County and the state of N.C. Cook Medical said it expects the deal to close during the third quarter. “To turn part of the R.J...
Source: Mass Device - June 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cook Medical Source Type: news

Fresenius Medical Care, Humacyte ink $150m strategic partnership deal
Fresenius Medical Care (NYSE:FMS; ETR:FRE) said today it inked a $150 million strategic partnership deal with Humacyte through which Fresenius will gain exclusive rights to commercialize Humacyte’s Humacyl bioengineered blood vessel technology. Research Triangle Park, N.C.-based Humacyte is exploring the use of its Humacyl human acellular vessel as a conduit for hemodialysis in patients with end-stage renal disease who cannot have fistula placement. Fresenius Medical will now be responsible for the marketing, sales and distribution of Humacyl following appropriate regulatory approval, the companies said. Fr...
Source: Mass Device - June 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Vascular Fresenius Humacyte Source Type: news

Obalon touts gas-filled gastric balloon after FDA notice of deaths related to liquid-filled balloons
Obalon Therapeutics (NSDQ:OBLN) today touted that it has never received a report of a death related to the use of its Obalon six-month gas-filled gastric balloon system designed to aid in weight loss in light of a recent FDA notice warning of five deaths related to liquid-filled gastric balloon systems. The San Diego-based company clarified that the FDA notice released earlier this week, which mentioned deaths related to the use of both Apollo Endosurgery (NSDQ:APEN) and ReShape Lifesciences (NSDQ:RSLS) liquid-filled gastric balloon devices, did not apply to its gas-filled balloons. “Our first con...
Source: Mass Device - June 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blog obalon Source Type: news

Philips Bets Big on Image-Guided Therapy with Latest Acquisition
Royal Philips is seeking to expand its image-guided therapy solutions with the acquisition EPD Solutions. Philips is set to acquire the Tortola, British Virgin Islands-based company for about $292 million upfront. The deal could close in July, Philips said. EPD’s cardiac imaging and navigation system has received CE mark and is used in diagnostic and therapeutic procedures for cardiac arrhythmias. The system has not been given a nod from FDA and is currently under review by the agency. Philips said its interventional imaging systems, such as Azurion, and EPD’s cardiac imaging and navigation system could more ef...
Source: MDDI - June 5, 2018 Category: Medical Devices Authors: Omar Ford Tags: Imaging Cardiovascular Source Type: news

AtriCure inks multi-year Chinese distro deal with Baheal Pharma
AtriCure (NSDQ:ATRC) said today it inked a multi-year partnership deal with China’s Baheal Pharmaceutical Group to distribute AtriCure’s surgical ablation devices. Through the deal, Baheal will become Mason, Ohio-based AtriCure’s exclusive distributor in the region, replacing the company’s previous distribution partner. “At Baheal, we’re continuously looking for ways to grow and expand our business. We believe that there is vast opportunity to treat patients and the market remains underpenetrated, and we’re confident that together, we are well positioned to grow and help more ...
Source: Mass Device - June 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution AtriCure Inc. Source Type: news

Neuronetics files for $86m IPO
Neuronetics yesterday registered an initial public offering worth more than $86 million with the U.S. Security & Exchange Commission, saying it plans to expand its commercialization efforts for the NeuroStar transcranial magnetic stimulation device for treating depression. The NeuroStar device uses MRI-strength magnetic fields to stimulate specific areas of the brain associated with mood. The device initially won 510(k) clearance from the FDA in December 2008, for treating adults with major depressive disorder who previously failed to respond to one medication. The federal safety watchdog expanded NeuroStar&r...
Source: Mass Device - June 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Neurological Wall Street Beat Neuronetics Source Type: news

Boston Scientific, IRS finalize $608m settlement over transfer pricing beef
Boston Scientific (NYSE:BSX) and the U.S. Internal Revenue Service yesterday finalized their settlement of a tax beef dating back to the $26 billion acquisition of Guidant in 2006, which would see the company pay nearly $610 million in taxes and interest. In transfer pricing, income is allocated among branches in different countries. It’s a legal tax maneuver companies can use to attribute profits from a product made and sold in the U.S. to a unit in a foreign country. In July 2016, Marlborough, Mass.-based Boston Scientific agreed to pay the IRS $275 million plus interest to put to bed a dis...
Source: Mass Device - May 31, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Legal News Wall Street Beat Boston Scientific U.S. Internal Revenue Service (IRS) Source Type: news

Boca Raton Regional Hospital earnings down as it considers merger
Boca Raton Regional Hospital had lower profits in its fiscal third quarter as it considers a partnership or merger with two South Florida health systems. The nonprofit hospital had net income of $2.8 million for the quarter ended March 31, compared to net income of $5.9 million in the same quarter a year ago, according to a report to bondholders. While its revenue increased to $142.6 million, from $136.6 million, BRRH’s expenses also grew. The co st of supplies increased 13.7 percent, which includes… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 29, 2018 Category: American Health Authors: Brian Bandell Source Type: news

Boca Raton Regional Hospital earnings down as it considers merger
Boca Raton Regional Hospital had lower profits in its fiscal third quarter as it considers a partnership or merger with two South Florida health systems. The nonprofit hospital had net income of $2.8 million for the quarter ended March 31, compared to net income of $5.9 million in the same quarter a year ago, according to a report to bondholders. While its revenue increased to $142.6 million, from $136.6 million, BRRH’s expenses also grew. The co st of supplies increased 13.7 percent, which includes… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 29, 2018 Category: Biotechnology Authors: Brian Bandell Source Type: news

Covalon is on the prowl, posts Q2 earnings
Covalon Technologies yesterday announced it is on the hunt for potential acquisitions alongside second quarter earnings results. The Ontario-based company said it formed a special board committee looking to evaluate possible strategic alliances, partnerships and acquisitions as a response to a $100 million contract the company recently won. “The board believes that the capital markets have not yet fully appreciated the impact of the highly transformative recent announcement of $100 million of contracted revenue over the next three years in addition to many other significant initiatives underway,” the company wr...
Source: Mass Device - May 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Mergers & Acquisitions Covalon Technologies Source Type: news

Medtronic's earnings beat estimates as sales of diabetes and heart devices rise
Medtronic ’s stock rose about 2 percent in afternoon trading after the company reported earnings that beat analyst expectations. The medical-device giant’s adjusted profit in the fourth quarter reached $1.44 per share, 5 cents higher than Wall Street estimates. The company’s revenue climbed to $8.14 bi llion for the fourth quarter, up about 3 percent compared to the year-ago period. Medtronic reported revenue growth across most of its business lines, with sales in its diabetes business leaping… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 24, 2018 Category: Pharmaceuticals Authors: Katharine Grayson Source Type: news

Medtronic tops estimates with fiscal Q4, 2018 results
Medtronic (NYSE:MDT) today reported fiscal fourth-quarter and 2018 numbers that beat Wall Street’s best guesses for sales and earnings. The Fridley, Minn.-based medical device giant posted profits of $1.46 billion, or $1.07 per share, on sales of $8.14 billion for the three months ended April 27, representing bottom-line growth of 25.5% on sales growth of 2.9% compared with the same period last year. Adjusted to exclude one-time items, earnings per share were $1.44, a full nickel ahead of The Street, where analysts were looking for sales of $7.74 billion. Full-year profits were $3.10 billion, or $2.27 per share, on s...
Source: Mass Device - May 24, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news